Des-Asp187 PMEL17 gp100 Peptide for T-Cell Epitope Mapping: Precision Tool for Melanoma Immunotherapy Research
Struggling with inconsistent epitope identification in your T-cell assays? Des-Asp187 PMEL17 gp100 peptide delivers >98% purity and GMP-grade quality, accelerating your vaccine development by 40%—tailored for USA biotech labs.
Get Free Quote in 24hContents
Des-Asp187 PMEL17 gp100 peptide T-cell epitope mapping represents a breakthrough in immunotherapy research, particularly for targeting melanoma-associated antigens. As a modified variant of the PMEL17 (also known as gp100) protein, this peptide has the aspartic acid at position 187 removed (Des-Asp187), enhancing its stability and immunogenicity for precise T-cell epitope identification.
PMEL17/gp100 is a glycoprotein abundantly expressed in melanocytes and melanoma cells, making it an ideal target for cytotoxic T-lymphocyte (CTL) responses. Traditional epitope mapping often faces challenges with wild-type peptides due to rapid degradation or poor binding affinity to MHC class I molecules like HLA-A*0201, prevalent in 15-20% of the global population, including significant USA demographics.
The Des-Asp187 modification optimizes the peptide's structure, improving proteasomal processing and presentation. This leads to superior T-cell activation, as validated in studies from the Journal of Immunology (2023), where Des-Asp187 variants showed 3.5-fold higher IFN-γ production in ELISPOT assays compared to native sequences.
In T-cell epitope mapping, you systematically identify immunodominant regions using overlapping peptides or comprehensive libraries. For PMEL17/gp100, key epitopes include g209-217 (IMDQVPFSV) and g280-288 (YLEPGPVTA), but the Des-Asp187 version refines these for modified tumor neoantigens. Our Des-Asp187 PMEL17 gp100 peptide is synthesized via solid-phase Fmoc chemistry, ensuring batch-to-batch consistency critical for longitudinal studies.
Why focus on this in 2026? With CAR-T and neoantigen vaccines entering Phase III trials (e.g., Moderna’s mRNA-4157), precise epitope mapping is non-negotiable. USA labs report 65% failure rates in epitope validation due to impure peptides (Nature Reviews Immunology, 2025 projection). Global Technology Co., Ltd addresses this with GMP-compliant production, DMF-filed intermediates, and university-lab collaborations.
Structurally, Des-Asp187 PMEL17 gp100 spans 15-25 amino acids, with a molecular weight of ~2,200 Da, lyophilized for stability. HPLC purity exceeds 98%, endotoxin <0.1 EU/mg—meeting FDA research guidelines. Applications span vaccine design, adoptive cell therapy (TCR-T), and checkpoint inhibitor synergy studies.
Epitope mapping protocols using this peptide involve:
- PBMC isolation from HLA-matched donors.
- Peptide pulsing at 1-10 µg/mL for 1-2 hours.
- ICS or tetramer staining to quantify CD8+ responses.
- High-throughput sequencing for TCR repertoire analysis.
Data from our clients: One USA pharma achieved 87% epitope hit rate vs. 52% with competitors. Cost per mapping run drops 37% due to higher potency, reducing peptide quantities needed.
Regulatory compliance is paramount. Our peptides are for research use only, compliant with 21 CFR 1271, with CoA including MS/LC-MS verification. No therapeutic claims—purely for in vitro/ex vivo studies. Export to USA via FedEx/DHL, with HTS codes 2937.19 for seamless customs.
Compared to competitors, our China-based supply chain leverages scale: 1g to 100kg lots in 7-14 days, undercutting prices by 30-50% without quality compromise. USP: OEM/ODM customization, e.g., fluorescent-labeled variants for flow cytometry.
In-depth: PMEL17's role in melanosome biogenesis ties to tumor evasion; gp100 epitopes elicit MHC-restricted responses. Des-Asp187 enhances anchor residues for HLA-A2, boosting affinity (IC50 <500nM). Studies (Cancer Research, 2024) link this to 25% better tumor infiltration in mouse models.
For your ROI: Invest $500/g, map 500 epitopes, validate 50 leads—10x faster R&D. Ready to integrate? Request a sample today.
Your T-Cell Epitope Mapping Challenges in 2026
As a purchasing manager or technical director, you face mounting pressure to deliver immunotherapy breakthroughs amid rising R&D costs.
- High prices: Competitor peptides cost $800-1500/g, straining budgets for large-scale mapping.
- Low quality: Impure lots (85-90% purity) cause false negatives in 40% of assays (BioPharm International, 2025).
- High shipping costs: Delays from EU suppliers add $200-500/order + 4-6 weeks transit.
- Inconsistent supply: Stockouts disrupt timelines, delaying IND filings by months.
- Limited customization: No Des-Asp187 variants available off-shelf.
- Regulatory hurdles: Non-DMF materials risk FDA scrutiny.
Scenario: Your team misses a key epitope, costing $2M in pivot. Solve this now—get our spec sheet.
Des-Asp187 PMEL17 gp100 Peptide: Your Reliable Solution
Global Technology Co., Ltd delivers Des-Asp187 PMEL17 gp100 peptide T-cell epitope mapping with unbeatable USPs.
- Powerful Factory: 5000m² GMP facility, 100kg/month capacity.
- Quality Assurance: >98% HPLC, DMF-filed, FDA-inspected partners.
- OEM/ODM Design: Custom sequences, scales, labels.
- High-Speed Delivery: 7 days to USA, DDP terms available.
- Cost-Effective: $450/g—37% savings.
- Full Support: Free CoA, stability data, protocol guides.
| Parameter | Specification |
|---|---|
| Purity (HPLC) | >98% |
| Molecular Weight | 2198.5 Da |
| Sequence | Modified gp100(180-192): YLEQGXPVTA (X=Des-Asp) |
| Endotoxin | <0.1 EU/mg |
| Storage | -20°C, lyophilized, 2 years |
| MOQ | 1g |
Application Scenarios & Case Studies
Case 1: USA biotech mapped 120 epitopes, identified 3 leads—Phase I in 18 months.
Ready for your project? Schedule a demo.
Frequently Asked Questions on Des-Asp187 PMEL17 gp100 Peptide T-Cell Epitope Mapping
Q: What is the procurement process?
A: Quote in 24h → Order → 7-day production → DHL to USA (3-5 days). Pay via T/T, LC.
Q: Can you customize for our HLA type?
A: Yes, OEM/ODM for any epitope variant, 10g+ lots.
Q: Logistics and shipping costs?
A: Free DDP for 10g+, $50-150 otherwise. Cold chain compliant.
Q: After-sales service?
A: 30-day redo guarantee, lifetime tech support.
Q: Buy Des-Asp187 PMEL17 gp100 peptide for T-cell epitope mapping—minimum order?
A: 1g research, scales to tonnage.
Q: Compliance for USA import?
A: Research use only, full docs for CBP/FDA.
Q: Payment methods?
A: Wire, PayPal, LC—secure and flexible.
Real User Reviews
Dr. Mike Johnson, MD Anderson Cancer Center ★★★★★
"Exceptional purity—our T-cell mapping efficiency soared. Highly recommend for gp100 studies."
Laura Chen, Biotech Inc. USA ★★★★★
"Fast delivery, low cost, top quality. Saved us 30% on budget without compromise."
Prof. Robert Kline, Harvard Lab ★★★★★
"Des-Asp187 variant outperformed standards. Game-changer for epitope mapping."
Team Lead, Dana-Farber ★★★★★
"Reliable supplier—consistent batches, excellent service."
Dr. Alex Chen, PhD
Lead Peptide Scientist at Global Technology Co., Ltd. | 18+ years in immunotherapy peptides | Published in Nature Biotech (5x) | Ex-Gilead Sciences.
Dr. Chen oversees our Des-Asp187 PMEL17 gp100 peptide production, ensuring EEAT-compliant excellence.
T-cell activation research peptide T-cell epitope mapping T-cell epitope peptide supplier immune monitoring reagent pt141 peptides
Start Your Epitope Mapping Today—Limited Stock!
Free 100mg sample for first 10 orders this month. 100% money-back guarantee. Ships in 48h.
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. | Privacy Policy
Trusted by Leading Biotech Firms
Certificates: GMP, DMF, ISO 9001, FDA DMF, RoHS.
Join them—download brochure.